|
|
|||||||||
Dr. Shih is Associate Professor, Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dr. Halpern is Strategic Director, Health Services Research, American Cancer Society, Atlanta, GA.
Disclosure: No outside financial support was provided for this manuscript, and no conflict of interest exists.
Published online through CA First Look at http://CAonline.AmCancer.Soc.org.
To earn free CME credit for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.
While the past decade has seen the development of multiple new interventions to diagnose and treat cancer, as well as to improve the quality of life for cancer patients, many of these interventions have substantial costs. This has resulted in increased scrutiny of the costs of care for cancer, as well as the costs relative to the benefits for cancer treatments. It is important for oncologists and other members of the cancer community to consider and understand how economic evaluations of cancer interventions are performed and to be able to use and critique these evaluations. This review discusses the components, main types, and analytic issues of health economic evaluations using studies of cancer interventions as examples. We also highlight limitations of these economic evaluations and discuss why members of the cancer community should care about economic analyses.
This article has been cited by other articles:
![]() |
D. Greenberg, C. Earle, C.-H. Fang, A. Eldar-Lissai, and P. J. Neumann When is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology J Natl Cancer Inst, January 20, 2010; 102(2): 82 - 88. [Abstract] [Full Text] [PDF] |
||||
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |